Processing

Please wait...

Settings

Settings

Goto Application

1. WO2004039837 - CRH RESPONSIVE GENES IN CNS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS:

1. A method of diagnosing a CRH induced gene expression profile in an individual said method comprising;
a) obtaining a biological sample of said individual; and
b) determine the level of gene transcription of a gene comprising a nucleic acid sequence selected from the group consisting of SEQ DD No.l, SEQ DD No.2,
SEQ DD No.3, SEQ DD No.4, SEQ ID NO.5, SEQ ED NO.6, SEQ ID No.7, SEQ ED No.8, SEQ DD NO.9, SEQ DD 11, SEQ DD NO.13, SEQ DD NO.15, SEQ D
NO.17, SEQ DD NO.19, SEQ ED NO.21, SEQ TD NO.23, SEQ TD No.25, SEQ
ED No.26, SEQ DD No.27, SEQ DD No.28, SEQ DD No.29, SEQ DD No.30, SEQ
DD No.31, SEQ DD NO.32, SEQ ED NO.34, SEQ DD NO.36, SEQ DD No.38 and SEQ ED No.40.

2. A method according to claim 1 wherein the biological sample is a bodily fluid or tissue sample

3. A method according to claims 1 or 2 wherein the level of gene transcription is determined for the genes having the nucleic acid sequences consisting of SEQ
ID No.l, SEQ ED No.2, SEQ ID No.3, SEQ ID No.4, SEQ DD NO.5, SEQ DD
NO.6, SEQ DD No.7, SEQ ED No.8, SEQ ID NO.9, SEQ DD 11, SEQ DD NO.13, SEQ DD NO.15, SEQ ED NO.17, SEQ DD NO.19, SEQ DD NO.21, SEQ DD
NO.23, SEQ DD No.25, SEQ DD No.26, SEQ ED No.27, SEQ DD No.28, SEQ ED No.29, SEQ DD No.30, SEQ DD No.31, SEQ DD NO.32, SEQ DD NO.34, SEQ DD

NO.36, SEQ DD No.38 and SEQ DD No.40.

4. A method according to claims 1 or 2 wherein the level of gene transcription is being assessed using a probe which binds to a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ D No.l, SEQ

DD No.2, SEQ DD No.3, SEQ ID No.4, SEQ ED NO.5, SEQ DD NO.6, SEQ ID No.7, SEQ ED No.8, SEQ DD NO.9, SEQ DD 11, SEQ DD NO.13, SEQ DD NO.15, SEQ ED NO.17, SEQ ED NO.19, SEQ ID NO.21, SEQ ED NO.23, SEQ DD No.25, SEQ ED No.26, SEQ ED No.27, SEQ ED No.28, SEQ ID No.29, SEQ ID No.30, SEQ ID No.31, SEQ ID NO.32, SEQ ID NO.34, SEQ TD NO.36,

SEQ πD No.38 and SEQ DD No.40.

5. A method according to any one of claims 1 to 4 wherein the level of gene
expression is determined using microarray technology.

6. A method of diagnosing a CRH induced gene expression profile in an individual said method comprising;
a) obtaining a biological sample of said individual; and
b) determine the amount of at least one protein that modulates corticotropin releasing hormone (CRH) signaling in said biological sample;
whereby the protein that modulates corticotropin releasing hormone (CRH) signaling is being selected from the group consisting of SEQ DD NO.10, SEQ ED 12, SEQ ED NO.14, SEQ DD NO.16, SEQ DD NO.18, SEQ DD NO.20, SEQ ED NO.22, SEQ π NO.24, SEQ ID NO.33, SEQ ID NO.35, SEQ DD NO.37, SEQ DD No.39 and SEQ DD No.41.

7. A method according to claim 6 wherein the biological sample is a bodily fluid or tissue sample

8. A method according to claims 6 or 7 wherein wherein the amount of protein that modulates CRH signaling is being determined using an antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ DD NO.10, SEQ ID 12, SEQ ID NO.14, SEQ DD NO.16, SEQ DD NO.18, SEQ DD NO.20, SEQ DD NO.22, SEQ DD NO.24, SEQ DD NO.33, SEQ DD NO.35, SEQ DD NO.37, SEQ DD No.39 and SEQ DD No.41.

9. A method according to claims 6 or 7 wherein the amount of protein that modulates CRH signaling is being determined by assessing the level of gene transcription of a gene encoding an amino acid sequence selected from the group consisting of SEQ DD NO.10, SEQ DD 12, SEQ DD NO.14, SEQ DD NO.16, SEQ DD NO.18, SEQ DD NO.20, SEQ DD NO.22, SEQ DD NO.24, SEQ

DD NO.33, SEQ DD NO.35, SEQ ED NO.37, SEQ DD No.39 and SEQ DD No.41.

10. A method according to claim 9 wherein the level of gene transcription is being assessed using a probe which binds to a polynucleotide encoding an amino acid sequence selected from the group consisting of SEQ HD NO.10, SEQ DD 12, SEQ HD NO.14, SEQ DD NO.16, SEQ DD NO.18, SEQ ED NO.20, SEQ HD NO.22, SEQ ED NO.24, SEQ DD NO.33, SEQ DD NO.35, SEQ DD NO.37, SEQ

HD NO.39 and SEQ DD No.41.

11. A method according to claim 10 wherein the level of gene expression is
determined using microarray technology.

12. A method according to claim 11 wherein the level of gene transcription is
analysed using an array of oligonucleotide probes that bind to the
polynucleotides encoding the group of polypeptides having the amino acid
sequences SEQ DD NO.10, SEQ DD 12, SEQ DD NO.14, SEQ DD NO.16, SEQ DD NO.18, SEQ DD NO.20, SEQ DD NO.22, SEQ DD NO.24, SEQ ID NO.33, SEQ
ED NO.35, SEQ ID NO.37, SEQ TD No.39 and SEQ DD No.41.

13. A method according to claim 11 wherein the level of gene transcription is
analysed using an array of oligonucleotide probes that bind to the
polynucleotides having the nucleic acid sequences SEQ DD No.l, SEQ ED No.2,

SEQ DD No.3, SEQ DD No.4, SEQ ED NO.5, SEQ DD NO.6, SEQ DD No.7, SEQ HD NO.8, SEQ DD NO.9, SEQ DD 11, SEQ DD NO.13, SEQ DD NO.15, SEQ DD
NO.17, SEQ DD NO.19, SEQ DD NO.21, SEQ DD NO.23, SEQ DD No.25, SEQ
DD No.26, SEQ DD No.27, SEQ DD No.28, SEQ DD No.29, SEQ ID No.30, SEQ
ED No.31, SEQ ED NO.32, SEQ DD NO.34, SEQ DD NO.36, SEQ ED No.38 and

SEQ DD No.40.

14. A method for identifying a compound capable to alter the CRH signalling response in a cell, said method comprising;
a) contacting said cell with CRH in the presence and absence of said compound; b) determine the amount of at least one protein that modulates corticotropin releasing hormone (CRH) signaling in said cell; and
c) compare the amount of said protein in the presence and absence of said compound;

whereby the protein that modulates corticotropin releasing hormone (CRH) signaling is being selected from the group consisting of SEQ ED NO.10, SEQ DD 12, SEQ DD NO.14, SEQ DD NO.16, SEQ ED NO.18, SEQ TD NO.20, SEQ DD NO.22, SEQ DD NO.24, SEQ ED NO.33, SEQ DD NO.35, SEQ DD NO.37, SEQ ED No.39 and SEQ TD No.41.

15. A method according to claim 13 wherein the cell is a eukaryotic cell such as the murine pituitary corticotroph-derived adenoma cell line AtT-20.

16. A method according to claims 13 or 14 wherein the amount of protein that modulates CRH signaling is being determined using an antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ DD NO.10, SEQ DD 12, SEQ DD NO.14, SEQ DD NO.16, SEQ DD NO.18, SEQ ED NO.20, SEQ ID NO.22, SEQ DD NO.24, SEQ ED NO.33, SEQ DD NO.35, SEQ DD NO.37, SEQ DD No.39 and SEQ DD No.41.

17. A method according to claims 13 or 14 wherein the amount of protein that modulates CRH signaling is being determined by assessing the level of gene transcription of a gene encoding an amino acid sequence selected from the group consisting of SEQ DD NO.10, SEQ DD 12, SEQ DD NO.14, SEQ ID NO.16, SEQ DD NO.18, SEQ ED NO.20, SEQ ED NO.22, SEQ DD NO.24, SEQ ED NO.33, SEQ DD NO.35, SEQ DD NO.37, SEQ DD No.39 and SEQ ED No.41.

18. A method according to claim 16 wherein the level of gene transcription is being assessed using a probe which binds to a polynucleotide encoding an amino acid sequence selected from the group consisting of SEQ DD NO.10, SEQ DD 12, SEQ DD NO.14, SEQ DD NO.16, SEQ DD NO.18, SEQ DD NO.20, SEQ DD NO.22, SEQ DD NO.24, SEQ DD NO.33, SEQ DD NO.35, SEQ DD NO.37, SEQ DD No.39 and SEQ DD No.41.

19. A method according to claims 16 or 17 wherein the level of gene expression is analysed using microarray technology.

20. A method according to claim 18 wherein the level of gene transcription is analysed using an array of oligonucleotide probes that bind to the
polynucleotides encoding the group of polypeptides having the amino acid sequences SEQ ED NO.10, SEQ DD 12, SEQ DD NO.14, SEQ DD NO.16, SEQ
DD NO.18, SEQ DD NO.20, SEQ DD NO.22, SEQ DD NO.24, SEQ DD NO.33, SEQ DD NO.35, SEQ DD NO.37, SEQ DD No.39 and SEQ ID No.41.

21. A method according to claim 18 wherein the level of gene transcription is analysed using an array of oligonucleotide probes that bind to the
polynucleotides having the nucleic acid sequences SEQ ED No.l, SEQ DD
No.2, SEQ DD No.3, SEQ DD No.4, SEQ DD NO.5, SEQ ED NO.6, SEQ DD
No.7, SEQ DD No.8, SEQ DD NO.9, SEQ DD 11, SEQ DD NO.13, SEQ ED
NO.15, SEQ DD NO.17, SEQ DD NO.19, SEQ DD NO.21, SEQ DD NO.23, SEQ DD No.25, SEQ DD No.26, SEQ TD No.27, SEQ DD No.28, SEQ DD No.29,
SEQ DD No.30, SEQ DD No.31, SEQ DD NO.32, SEQ DD NO.34, SEQ DD
NO.36, SEQ DD No.38 and SEQ ED No.40.

22. A method for identifying a compound capable to alter the CRH signalling response activity in a cell, said method comprising;
a) contacting a cell which expresses at least one protein comprising an amino acid sequence selected from the group consisting of SEQ DD NO.10, SEQ DD 12, SEQ DD NO.14, SEQ DD NO.16, SEQ D NO.18, SEQ DD NO.20, SEQ DD NO.22, SEQ DD NO.24, SEQ DD NO.33, SEQ DD NO.35, SEQ DD NO.37, SEQ DD No.39 and SEQ DD No.41, with said test compound; and
b) compare the CRH response activity of said cell in the presence and absence of said compound.

23. A method according to claim 21 wherein the cell is a host cell capable to express at least one protein having an amino acid sequence selected from the group consisting of SEQ DD NO.10, SEQ ED 12, SEQ ED NO.14, SEQ DD NO.16, SEQ DD NO.18, SEQ DD NO.20, SEQ DD NO.22, SEQ DD NO.24, SEQ DD NO.33, SEQ ID NO.35, SEQ DD NO.37, SEQ DD No.39 and SEQ ID No.41.

24. A method according to claim 22 wherein the host cell is transfected with at least one vector comprising a regulatory sequence.

25. A method according to claim 22 wherein the host cell is transfected with at least one vector comprising a polynucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ D NO.10, SEQ ED 12, SEQ DD NO.14, SEQ DD NO.16, SEQ DD NO.18, SEQ DD NO.20, SEQ DD NO.22, SEQ DD NO.24, SEQ DD NO.33, SEQ DD NO.35, SEQ DD NO.37, SEQ DD No.39 and SEQ DD No.41.

26. An isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ DD No.l, SEQ DD No.2, SEQ DD No.3, SEQ DD No.4, SEQ DD No.5, SEQ DD No.6, SEQ DD No.7, SEQ D No.8, SEQ DD No.25, SEQ DD No.26, SEQ DD No.27, SEQ DD No.28, SEQ DD No.29, SEQ DD No.30 and SEQ DD No.31, for use as a marker of CRH signaling in a cell.

27. An isolated polynucleotide according to claim 21 wherein said polynucleotide is mRNA, DNA or cDNA.

28. An isolated polynucleotide consisting of a nucleic acid sequence selected from the group consisting of SEQ ID No.l, SEQ DD No.2, SEQ DD No.3, SEQ DD No.4, SEQ DD No.5, SEQ DD No.6, SEQ DD No.7, SEQ D No.8, SEQ DD No.25, SEQ DD No.26, SEQ ED No.27, SEQ DD No.28, SEQ DD No.29, SEQ DD No.30 and SEQ ED No.31, for use as a marker of CRH signaling in a cell.

29. A vector comprising an isolated polynucleotide according to any one of claims 25 to 27.

30. A vector according to claim 28 wherein the polynucleotide is operably linked to an expression control sequence.

31. A host cell transfected with a vector according to claims 28 or 29.